Related Experiment Video
Updated: Jun 19, 2026
07:54
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Multimodality strategies in malignant pleural mesothelioma
Walter Weder1, Isabelle Opitz, Rolf Stahel
1Division of Thoracic Surgery, University Hospital Zurich, Zürich, Switzerland. walter.weder@chi.usz.ch
Seminars in Thoracic and Cardiovascular Surgery
|October 14, 2009
Summary
Recent advancements enhance malignant pleural mesothelioma treatment. Multimodality strategies, including extrapleural pneumonectomy (EPP) and pleurectomy/decortication with chemotherapy, show improved survival outcomes.
Area of Science:
- Thoracic Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Significant progress in malignant pleural mesothelioma (MPM) diagnosis and treatment over the past decade.
- Improved understanding of MPM tumor biology and enhanced chemotherapeutic agents.
- Advances in surgical techniques and multidisciplinary therapeutic approaches.
Purpose of the Study:
- To review current strategies for managing malignant pleural mesothelioma.
- To discuss the role of radical tumor resection, including extrapleural pneumonectomy (EPP) and pleurectomy/decortication.
- To highlight the benefits of neoadjuvant and adjuvant therapies in multimodality treatment plans.
Main Methods:
- Review of contemporary literature on malignant pleural mesothelioma management.
- Discussion of surgical techniques: extrapleural pneumonectomy (EPP) and pleurectomy/decortication.
- Analysis of neoadjuvant and adjuvant treatment strategies in conjunction with surgery.
Main Results:
- Extrapleural pneumonectomy (EPP) is feasible with acceptable outcomes in specialized centers, even post-neoadjuvant chemotherapy.
- Multimodality treatment strategies incorporating surgical resection yield the best reported survival data for MPM.
- Combined approaches involving EPP or pleurectomy/decortication with adjuvant/neoadjuvant therapies are central to improved patient outcomes.
Conclusions:
- Multimodality treatment, including radical surgical resection, is crucial for optimizing survival in malignant pleural mesothelioma.
- Extrapleural pneumonectomy (EPP) and pleurectomy/decortication, when combined with chemotherapy and other therapies, represent effective management options.
- Continued research and specialized center care are vital for advancing MPM treatment.
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations: